# Do GLP-1s reduce alcohol cravings? What the trials found

Source: https://pepvault.app/guides/glp-1-and-alcohol-cravings

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Do GLP-1s reduce alcohol cravings? What the trials found

Reviewed November 2026 26 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Do GLP-1s cut alcohol cravings? What the semaglutide, exenatide and dulaglutide trials found, the health-record data, the trials running now, and the labels.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 26
- **Questions:** 8
- **Compounds:** 7

## The short answer

In the trials so far, mostly yes. As of November 2026, three randomized semaglutide trials found less craving or less heavy drinking than placebo; the largest, in 108 adults with obesity over 26 weeks, cut heavy drinking days by 13.7 percentage points more than placebo. An earlier exenatide trial missed its main goal. No GLP-1 is approved for alcohol use, so treatment stays a prescriber's call.

Every number checked at its primary source · Nov 20, 2026 · [26 sources](https://pepvault.app/guides/glp-1-and-alcohol-cravings#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Six placebo-controlled trials in people who drink heavily (four semaglutide or exenatide trials in alcohol use disorder, one dulaglutide secondary analysis, one company-reported pemvidutide topline), large health-record studies that show association rather than cause, a meta-analysis, surveys and a case series, and rodent and monkey studies for the brain pathway; no phase 3 result yet.

## Why would a weight-loss drug change drinking?

Alcohol feels rewarding because it releases **dopamine**, a chemical messenger, in the brain's reward circuit, a pathway that runs into the **nucleus accumbens**, a small hub deep in the brain that tags things as worth repeating. GLP-1 drugs act on a gut hormone's receptor, and those receptors also sit in this circuit. When the drug reaches them, a drink pays out less: in animals, alcohol releases less dopamine there.

The animal work shows each step. In rats, a fluorescently tagged copy of semaglutide reached the nucleus accumbens, and semaglutide cut alcohol intake and blocked relapse-like drinking in males and females; in mice it stopped alcohol from raising dopamine there[12](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-12). Semaglutide also cut binge-like and dependence-driven drinking in mice and rats[13](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-13), and in 20 alcohol-preferring male vervet monkeys it lowered how much they chose to drink, with no vomiting and no change in water intake[14](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-14). Tirzepatide, which also acts on the receptor for a second gut hormone, GIP, did the same in rodents, including blocking relapse-like drinking[15](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-15). These are animal results.

The human evidence points at the same circuit. In the exenatide trial below, brain scans showed a weaker response to pictures of alcohol in the ventral striatum, the region that holds the nucleus accumbens, than on placebo[4](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-4). The appetite side of the same story, the quieting of food thoughts, has its own guide: Food noise on a GLP-1.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

The daily check-in on PepVault's Today screen has a note field: write the day's drinks there. Each note is saved to its day, and PepTalk reads your notes beside the doses you logged.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What did the randomized trials find?

Six placebo-controlled trials have reported drinking results. A **heavy drinking day** means 4 or more drinks for a woman or 5 or more for a man in the 2025 US trial[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2); the Danish trials counted it in grams of alcohol[1](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-1). All but the pemvidutide trial have been peer reviewed.

| Trial | Who and how long | Drug and dose | Main result against placebo |
| --- | --- | --- | --- |
| Klausen 2022, Denmark | 127 adults seeking treatment for alcohol use disorder, 26 weeks, with talk therapy | Exenatide 2 mg weekly | No significant drop in heavy drinking days (the main goal); fewer heavy drinking days and less total alcohol in the subgroup with a BMI over 30, an exploratory finding[4](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-4) |
| Probst 2023, Switzerland | 151 drinkers in a stop-smoking trial, 12 weeks | Dulaglutide 0.75 mg the first week, then 1.5 mg weekly | 29% less alcohol drunk at week 12[5](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-5) |
| Hendershot 2025, US | 48 adults with alcohol use disorder not seeking treatment, 9 weeks | Semaglutide injection, 0.25 mg weekly for 4 weeks, then 0.5 mg (1.0 mg in the last week) | Less alcohol drunk in a lab drinking session (the main goal); fewer drinks per drinking day and less weekly craving; no change in how many days people drank[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2) |
| Schacht 2026, US | 50 adults with moderate to severe alcohol use disorder seeking treatment, 8 weeks | Oral semaglutide, 3 mg then 7 mg daily | No change in lab craving (the main goal) or drinks per day; fewer heavy drinking days, fewer drinks per drinking day, less everyday craving[3](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-3) |
| Klausen 2026, Denmark (Lancet) | 108 adults with moderate to severe alcohol use disorder and obesity, 26 weeks, with talk therapy | Semaglutide up to 2.4 mg weekly | Share of heavy drinking days down 41.1 percentage points from baseline against 26.4 on placebo, a 13.7-point difference (the main goal)[1](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-1) |
| RECLAIM 2026, US (company topline) | About 100 adults with alcohol use disorder and a BMI over 25, 24 weeks | Pemvidutide 2.4 mg weekly (GLP-1 plus glucagon) | Heavy drinking days down 4.20 a week against 2.75; 64.4% against 34.8% dropped two drinking-risk levels[6](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-6) |

In both US semaglutide trials the clearest change was in how much people drank once they started: drinks per drinking day fell, while the number of drinking days[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2) and drinks per calendar day[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2) [3](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-3) did not change significantly. The clearest result so far came in a 26-week trial at the full weight-loss dose, in people with obesity[1](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-1), and the exenatide trial's only clear signal was in its subgroup with obesity too[4](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-4).

Exenatide is an older GLP-1 drug, and even with the miss its trial saw a calmer reward response on brain scans and less dopamine transporter, a marker of dopamine signaling, than placebo[4](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-4). Our page on that trial has the detail: Exenatide for alcohol use disorder: 26-week trial results.

## What do the health-record studies show?

Large records studies point the same way, across millions of patients. They show an association, not proof: people who are prescribed a GLP-1 may differ from people who are not.

- **US, 83,825 patients with obesity:** semaglutide was linked to a 50-56% lower risk of a first or repeat alcohol use disorder diagnosis over 12 months than other weight-loss drugs; the pattern held in 598,803 patients with type 2 diabetes[7](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-7).
- **Sweden, 227,866 people with alcohol use disorder:** during the months they took semaglutide, their risk of an alcohol-related hospital stay was 36% lower than when they did not (hazard ratio 0.64), and 28% lower on liraglutide; the approved alcohol medicines together lowered it by about 2%[8](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-8).
- **US, 817,309 patients with alcohol use disorder:** a GLP-1 or GIP/GLP-1 prescription went with half the rate of alcohol intoxication[9](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-9).
- **US veterans:** drinking scores fell more on a GLP-1 than on no drug or on DPP-4 inhibitors, a different diabetes pill, most of all in people who drank heavily at the start[10](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-10).

A 2025 meta-analysis pooled 14 studies, 4 randomized and 10 observational, and found drinking-problem scores (the AUDIT, scored 0 to 40) lower by 7.8 points on average with a GLP-1, with wide variation between studies[11](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-11).

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

## Does it work if you don't have obesity?

That is the open question. The Lancet trial enrolled only people with a BMI of 30 or more[1](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-1), and exenatide's benefit showed only in that group[4](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-4). The 2025 US trial set its floor at a BMI of 23 and averaged 32; 21 of its 48 participants had a BMI under 30, and the authors did not report a separate result for them[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2). The pemvidutide trial took people with a BMI over 25[6](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-6). The records studies are mostly people with obesity or type 2 diabetes, because those are the people who get these drugs[7](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-7) [8](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-8).

No GLP-1 drug is approved for alcohol use. Wegovy's label lists weight, heart and liver uses, and Zepbound's weight and sleep apnea; neither lists drinking[18](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-18) [19](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-19). The US has three approved medicines for alcohol use disorder: naltrexone, acamprosate and disulfiram[20](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-20).

## Which trials are running now?

As of November 2026, ClinicalTrials.gov lists larger and longer trials than any so far, including the first phase 3 trials, the last stage before a drug company can ask for approval.

| Trial | Drug | Size and length | Status (registry, November 2026) |
| --- | --- | --- | --- |
| Two Eli Lilly phase 3 trials (NCT07219966, NCT07219953) | Brenipatide, an investigational injection under the skin; the registry does not name its drug class | About 1,100 people each, about 56 weeks in the study | Recruiting[22](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-22) [23](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-23) |
| US Veterans Affairs phase 3 (NCT07218354) | Semaglutide up to 2.4 mg weekly | 622 veterans, 24 weeks of treatment | Recruiting[24](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-24) |
| Eli Lilly phase 2 (NCT06817356) | Mazdutide (GLP-1 plus glucagon) | 308 people | Completed; no results posted[25](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-25) |
| University of Southern California phase 2 (NCT06994338) | Tirzepatide | 42 adults with overweight or obesity, 8 weeks | Recruiting, by a record last updated in October 2025[26](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-26) |

## What do people on a GLP-1 report about drinking?

These are reports, not trials. Researchers who sorted 1,580 alcohol-related Reddit posts about semaglutide and tirzepatide with a machine-learning tool found that 72% described less craving, less drinking or other negative effects of drinking, such as feeling sick or full[16](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-16). In the same study, 153 drinkers with obesity on either drug reported fewer drinks per occasion, lower odds of binge drinking and weaker buzz and sedation from alcohol than before starting and than people not on the drugs[16](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-16). In a chart review of 6 people with a positive alcohol screen who started semaglutide for weight loss, every one improved, by 9.5 AUDIT points on average[17](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-17).

**Commonly reported:** the second and third drink losing their pull, a glass left half full, feeling full or a little queasy after one drink, and nights out ending earlier without any effort to cut back.

## Is it safe to drink alcohol on a GLP-1?

Neither the Wegovy nor the Zepbound label lists alcohol as an interaction[18](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-18) [19](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-19). In the 2025 semaglutide trial, people drank in a supervised lab session on the drug: they drank less and reached a lower peak breath alcohol, with no serious side effects and no harmful interactions with alcohol recorded[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2). Across the trials the side effects were the usual ones for these drugs, mostly mild to moderate stomach effects such as nausea[1](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-1) [4](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-4); in the pemvidutide trial, nausea came in 44% against 24% on placebo[6](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-6).

## How can you track your drinking on a GLP-1?

The trials measured drinking with a day-by-day calendar of drinks, and the same record works at home. It shows your prescriber what changed, and when, around each dose step.

1. Count in standard drinks: one US standard drink is about 14 g of alcohol, which is a 12-ounce beer at 5%, a 5-ounce glass of wine at 12% or a 1.5-ounce shot of spirits at 40%[21](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-21).
2. Write down each day's total, including the days you drink nothing.
3. Mark the heavy days: 4 or more drinks for a woman, 5 or more for a man[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2).
4. Note the day of each injection and every dose change, so a shift can be lined up against the dose.
5. Once a month, count your heavy days and your drinks per drinking day, the two numbers that moved most in the trials[2](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-2) [3](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-3), and bring them to your next appointment.

<!--promo-->

The daily check-in on PepVault's Today screen has a note field: write the day's drinks there. Each note is saved to its day, and PepTalk reads your notes beside the doses you logged. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1-and-alcohol-cravings-inline&mt=8)

<!--/promo-->

**When to get help** If you drink heavily most days, speak with a doctor before cutting down quickly: after long heavy drinking, withdrawal can be dangerous, and a doctor can plan it safely[20](https://pepvault.app/guides/glp-1-and-alcohol-cravings#source-20).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026. [PubMed 42070571](https://pubmed.ncbi.nlm.nih.gov/42070571/)
2. Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025. [PubMed 39937469](https://pubmed.ncbi.nlm.nih.gov/39937469/)
3. Schacht JP et al. Oral semaglutide for alcohol use disorder: a randomized clinical trial. Am J Psychiatry. 2026. [PubMed 42522065](https://pubmed.ncbi.nlm.nih.gov/42522065/)
4. Klausen MK et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022. [PubMed 36066977](https://pubmed.ncbi.nlm.nih.gov/36066977/)
5. Probst L et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023. [PubMed 37991022](https://pubmed.ncbi.nlm.nih.gov/37991022/)
6. Altimmune. Altimmune announces positive topline results from RECLAIM phase 2 trial of pemvidutide in alcohol use disorder. Press release, July 28, 2026. [biospace.com](https://www.biospace.com/press-releases/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder)
7. Wang W et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024. [PubMed 38806481](https://pubmed.ncbi.nlm.nih.gov/38806481/)
8. Lähteenvuo M et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025. [PubMed 39535805](https://pubmed.ncbi.nlm.nih.gov/39535805/)
9. Qeadan F et al. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders. Addiction. 2025. [PubMed 39415416](https://pubmed.ncbi.nlm.nih.gov/39415416/)
10. Farokhnia M et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J Clin Invest. 2025. [PubMed 40048376](https://pubmed.ncbi.nlm.nih.gov/40048376/)
11. Eshraghi R et al. Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. EClinicalMedicine. 2025. [PubMed 41324012](https://pubmed.ncbi.nlm.nih.gov/41324012/)
12. Aranäs C et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023. [PubMed 37295046](https://pubmed.ncbi.nlm.nih.gov/37295046/)
13. Chuong V et al. The GLP-1 analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023. [PubMed 37192005](https://pubmed.ncbi.nlm.nih.gov/37192005/)
14. Fink-Jensen A et al. Effect of the GLP-1 receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacology (Berl). 2025. [PubMed 38884652](https://pubmed.ncbi.nlm.nih.gov/38884652/)
15. Edvardsson CE et al. Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. EBioMedicine. 2026. [PubMed 41506148](https://pubmed.ncbi.nlm.nih.gov/41506148/)
16. Quddos F et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023. [PubMed 38017205](https://pubmed.ncbi.nlm.nih.gov/38017205/)
17. Richards JR et al. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series. J Clin Psychiatry. 2023. [PubMed 38019594](https://pubmed.ncbi.nlm.nih.gov/38019594/)
18. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, revised June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
19. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
20. National Institute on Alcohol Abuse and Alcoholism. Treatment for alcohol problems: finding and getting help. Updated February 2025. [niaaa.nih.gov](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help)
21. National Institute on Alcohol Abuse and Alcoholism. What is a standard drink? Updated December 2025. [niaaa.nih.gov](https://www.niaaa.nih.gov/alcohols-effects-health/what-standard-drink)
22. ClinicalTrials.gov. NCT07219966: A study of brenipatide in participants with moderate-to-severe alcohol use disorder (Eli Lilly). Last updated October 7, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219966)
23. ClinicalTrials.gov. NCT07219953: A study of brenipatide in participants with alcohol use disorder (Eli Lilly). Last updated November 4, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219953)
24. ClinicalTrials.gov. NCT07218354: Cessation or reduction of alcohol consumption in veterans: a randomized controlled trial of semaglutide (VA Office of Research and Development). Last updated September 21, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218354)
25. ClinicalTrials.gov. NCT06817356: A study to evaluate mazdutide compared with placebo in participants with alcohol use disorder (Eli Lilly). Last updated July 16, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06817356)
26. ClinicalTrials.gov. NCT06994338: Tirzepatide for alcohol use disorder (University of Southern California). Last updated October 14, 2025. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994338)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)

Wegovy is approved for MASH, the inflamed fatty liver. What semaglutide, tirzepatide, survodutide and retatrutide did to liver fat and scarring, side by side.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Exenatide Studied range: 5–10 mcg](https://pepvault.app/peptides/exenatide)
- [Dulaglutide Studied range: 0.75–4.5 mg](https://pepvault.app/peptides/dulaglutide)
- [Liraglutide Studied range: 0.6–3 mg](https://pepvault.app/peptides/liraglutide)
- [Pemvidutide Studied range: 1.2–2.4 mg](https://pepvault.app/peptides/pemvidutide)
- [Mazdutide Studied range: 2–6 mg](https://pepvault.app/peptides/mazdutide)

## Related guides

- Guide · GLP-1s

  ### [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)

  Food noise on a GLP-1: what the term means, how it is measured, what semaglutide and tirzepatide trials and users report, and what is known after stopping.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)

  What to expect on semaglutide week by week: the Wegovy label's dose steps, what the STEP trials saw at each stage, appetite, side effects and the plateau.

  Read the guide
- Guide · GLP-1s

  ### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

  What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
